Shopping Cart 0
Cart Subtotal
USD 0

Stada Arzneimittel AG (SAZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Stada Arzneimittel AG (STADA) is a manufacturer of low-cost generics and branded over the counter products. The company develops and markets drugs with off-patent active pharmaceutical ingredients, particularly, which are free from commercial property rights. It offers a portfolio of products in various therapeutic categories including pain, women's health, cardiovascular conditions and diabetes. Few of its major generic products include including Tilidin Naloxon, Atorvastatin, Pantoprazol, Epoetin zeta and Diclofenac. Its major branded products include APO-Go, Grippostad, Snup, Fultium, and Vitaprost. The company operates in more than 30 countries with sales in Germany, Central Europe, CIS/Eastern Europe and Asia-Pacific. STADA is headquartered in Bad Vilbel, Germany.

Stada Arzneimittel AG (SAZ)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Stada Arzneimittel AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Stada Arzneimittel AG, Medical Devices Deals, 2012 to YTD 2018 12

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deal Details 15

Asset Purchase 15

Stada Arzneimittel Acquires Nizoral from Janssen Pharma 15

STADA Arzneimittel Acquires AndroDoz and NeroDoz from OOO PharmEnergy for USD7.9 Million 16

Thornton & Ross Acquires Rights for Flexitol from LaCorium Health for USD17 Million 17

Nizhpharm Completes Acquisition Of Aqualor Product Portfolio For USD 178 Million 18

STADA Arzneimittel Completes Acquisition Of Generics Business From Spirig Pharma For USD 108 Million 19

STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For USD 230 Million 20

Private Equity 22

Bristol-Myers Squibb May Sell UPSA to BC Partners, CVC Capital, PAI Partners and STADA for USD1.16 Billion 22

Ardian May Sell Riemser Pharma for USD494.3 Million 24

Bain Capital and Cinven Partners to Acquire Stada Arzneimittel 26

Bain Capital Private Equity and Cinven Partners Renew the Terms to Acquire Stada Arzneimittel 28

Partnerships 30

Xbrane Biopharma and STADA Arzneimittel Enter into Co-Development Agreement 30

Enzymatica Enters into Distribution Agreement with STADA for ColdZyme 31

Theratechnologies Enters into Commercialization Agreement with BL&H 32

Stada Arzneimittel to Form Joint Venture with Hetero Drugs 33

Claris Lifesciences Enters into Distribution Agreement with Stada Arzneimittel 34

Licensing Agreements 35

BL&H Enters into Licensing Agreement with Race Oncology 35

BL&H Enter into Licensing Agreement with MDNA Life Sciences 36

Thornton & Ross Enters into Licensing Agreement with Futura Medical 37

BL&H Enters into Licensing Agreement with Telesta Therapeutics 38

STADA Arzneimittel Enters into Licensing Agreement with Gedeon Richter 39

Stada Arzneimittel to Enter into Licensing Agreement with mAbxience 40

Stada Arzneimittel Enters into Licensing Agreement with Richter-Helm BioTec 41

Stada Arzneimittel Enters Into License Agreement With Apotex For Filgrastim 42

Clinigen Enters Into Licensing Agreement With BL&H For Foscavir 44

Equity Offering 45

Telesta Therapeutics Raises USD0.2 Million in Private Placement of Shares 45

Debt Offering 46

Stada Arzneimittel Announces Private Placement of Bonds Due 2022 for USD325.5 46

Stada Arzneimittel Completes Private Placement Of Bonds Due 2018 For USD 452 Million 47

Asset Transactions 48

DMN Invest Acquires Two Drug Manufacturing Facilities From Stada Arzneimittel 48

Acquisition 49

Nidda Healthcare to Acquire Stake in Stada Arzneimittel 49

Elliott Management May Acquire Stake in Stada Arzneimittel 50

STADA Arzneimittel to Acquire Laboratorio Vannier for USD13 Million 51

STADA Arzneimittel Acquires SCIOTEC Diagnostic Technologies for USD19.8 Million 52

Stada Arzneimittel Completes Acquisition Of Thornton & Ross, OTC Drug Maker, For USD 339 Million 53

Sun Pharma Mulls Acquisition Of Stada Arzneimittel 55

Stada Arzneimittel AG-Key Competitors 56

Stada Arzneimittel AG-Key Employees 57

Stada Arzneimittel AG-Locations And Subsidiaries 58

Head Office 58

Other Locations & Subsidiaries 58

Recent Developments 61

Financial Announcements 61

Aug 09, 2018: STADA's business development in the first six months of 2018 as expected 61

May 03, 2018: STADA with solid business development in the first quarter of 2018 63

Mar 08, 2018: STADA records positive business development in 2017 65

Nov 09, 2017: STADA shows good business development in the third quarter of 2017 and the first nine months 68

Corporate Communications 70

Sep 03, 2018: Peter Goldschmidt to succeed Claudio Albrecht as STADA's CEO 70

Apr 16, 2018: Changes in the management team of STADA 71

Feb 01, 2018: Supervisory Board of STADA Arzneimittel appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018 72

Feb 01, 2018: Peter Goldschmidt to succeed Claudio Albrecht as CEO on 1 September 2018 73

Jul 04, 2017: STADA Arzneimittel appoints new Chief Executive Officer and Chief Financial Officer-incumbents step down from their positions 74

Apr 24, 2017: Dr. Ralph Grobecker to become Managing Director of STADA's OTC segment 75

Other Significant Developments 76

Sep 12, 2018: STADA invites the holders of the STADA Bond to participate in the bondholders meeting and to vote in favor of the proposed resolutions 76

Mar 08, 2018: CEO Albrecht to modernize STADA-Biosimilars to focus on oncology, CNS, diabetes and ophthalmology 77

Aug 03, 2017: STADA shows good operational development in first six months of 2017 78

Appendix 81

Methodology 81

About GlobalData 81

Contact Us 81

Disclaimer 81


List Of Figure

List of Figures

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Stada Arzneimittel AG, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Stada Arzneimittel AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Stada Arzneimittel AG, Deals By Therapy Area, 2012 to YTD 2018 10

Stada Arzneimittel AG, Medical Devices Deals, 2012 to YTD 2018 12

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Stada Arzneimittel Acquires Nizoral from Janssen Pharma 15

STADA Arzneimittel Acquires AndroDoz and NeroDoz from OOO PharmEnergy for USD7.9 Million 16

Thornton & Ross Acquires Rights for Flexitol from LaCorium Health for USD17 Million 17

Nizhpharm Completes Acquisition Of Aqualor Product Portfolio For USD 178 Million 18

STADA Arzneimittel Completes Acquisition Of Generics Business From Spirig Pharma For USD 108 Million 19

STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For USD 230 Million 20

Bristol-Myers Squibb May Sell UPSA to BC Partners, CVC Capital, PAI Partners and STADA for USD1.16 Billion 22

Ardian May Sell Riemser Pharma for USD494.3 Million 24

Bain Capital and Cinven Partners to Acquire Stada Arzneimittel 26

Bain Capital Private Equity and Cinven Partners Renew the Terms to Acquire Stada Arzneimittel 28

Xbrane Biopharma and STADA Arzneimittel Enter into Co-Development Agreement 30

Enzymatica Enters into Distribution Agreement with STADA for ColdZyme 31

Theratechnologies Enters into Commercialization Agreement with BL&H 32

Stada Arzneimittel to Form Joint Venture with Hetero Drugs 33

Claris Lifesciences Enters into Distribution Agreement with Stada Arzneimittel 34

BL&H Enters into Licensing Agreement with Race Oncology 35

BL&H Enter into Licensing Agreement with MDNA Life Sciences 36

Thornton & Ross Enters into Licensing Agreement with Futura Medical 37

BL&H Enters into Licensing Agreement with Telesta Therapeutics 38

STADA Arzneimittel Enters into Licensing Agreement with Gedeon Richter 39

Stada Arzneimittel to Enter into Licensing Agreement with mAbxience 40

Stada Arzneimittel Enters into Licensing Agreement with Richter-Helm BioTec 41

Stada Arzneimittel Enters Into License Agreement With Apotex For Filgrastim 42

Clinigen Enters Into Licensing Agreement With BL&H For Foscavir 44

Telesta Therapeutics Raises USD0.2 Million in Private Placement of Shares 45

Stada Arzneimittel Announces Private Placement of Bonds Due 2022 for USD325.5 46

Stada Arzneimittel Completes Private Placement Of Bonds Due 2018 For USD 452 Million 47

DMN Invest Acquires Two Drug Manufacturing Facilities From Stada Arzneimittel 48

Nidda Healthcare to Acquire Stake in Stada Arzneimittel 49

Elliott Management May Acquire Stake in Stada Arzneimittel 50

STADA Arzneimittel to Acquire Laboratorio Vannier for USD13 Million 51

STADA Arzneimittel Acquires SCIOTEC Diagnostic Technologies for USD19.8 Million 52

Stada Arzneimittel Completes Acquisition Of Thornton & Ross, OTC Drug Maker, For USD 339 Million 53

Sun Pharma Mulls Acquisition Of Stada Arzneimittel 55

Stada Arzneimittel AG, Key Competitors 56

Stada Arzneimittel AG, Key Employees 57

Stada Arzneimittel AG, Subsidiaries 58

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Stada Arzneimittel AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Stada Arzneimittel AG (STADA) is a manufacturer of low-cost generics and branded over the counter products. The company develops and markets drugs with off-patent active pharmaceutical ingredients, particularly, which are free from commercial property rights. It offers a portfolio of products in various therapeutic categories including pain, women's health, cardiovascular conditions and diabetes. Few of its major generic products include including Tilidin Naloxon, Atorvastatin, Pantoprazol, Epoetin zeta and Diclofenac. Its major branded products include APO-Go, Grippostad, Snup, Fultium, and Vitaprost. The company operates in more than 30 countries with sales in Germany, Central Europe, CIS/Eastern Europe and Asia-Pacific. STADA is headquartered in Bad Vilbel, Germany.

Stada Arzneimittel AG (SAZ)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Stada Arzneimittel AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Stada Arzneimittel AG, Medical Devices Deals, 2012 to YTD 2018 12

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deal Details 15

Asset Purchase 15

Stada Arzneimittel Acquires Nizoral from Janssen Pharma 15

STADA Arzneimittel Acquires AndroDoz and NeroDoz from OOO PharmEnergy for USD7.9 Million 16

Thornton & Ross Acquires Rights for Flexitol from LaCorium Health for USD17 Million 17

Nizhpharm Completes Acquisition Of Aqualor Product Portfolio For USD 178 Million 18

STADA Arzneimittel Completes Acquisition Of Generics Business From Spirig Pharma For USD 108 Million 19

STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For USD 230 Million 20

Private Equity 22

Bristol-Myers Squibb May Sell UPSA to BC Partners, CVC Capital, PAI Partners and STADA for USD1.16 Billion 22

Ardian May Sell Riemser Pharma for USD494.3 Million 24

Bain Capital and Cinven Partners to Acquire Stada Arzneimittel 26

Bain Capital Private Equity and Cinven Partners Renew the Terms to Acquire Stada Arzneimittel 28

Partnerships 30

Xbrane Biopharma and STADA Arzneimittel Enter into Co-Development Agreement 30

Enzymatica Enters into Distribution Agreement with STADA for ColdZyme 31

Theratechnologies Enters into Commercialization Agreement with BL&H 32

Stada Arzneimittel to Form Joint Venture with Hetero Drugs 33

Claris Lifesciences Enters into Distribution Agreement with Stada Arzneimittel 34

Licensing Agreements 35

BL&H Enters into Licensing Agreement with Race Oncology 35

BL&H Enter into Licensing Agreement with MDNA Life Sciences 36

Thornton & Ross Enters into Licensing Agreement with Futura Medical 37

BL&H Enters into Licensing Agreement with Telesta Therapeutics 38

STADA Arzneimittel Enters into Licensing Agreement with Gedeon Richter 39

Stada Arzneimittel to Enter into Licensing Agreement with mAbxience 40

Stada Arzneimittel Enters into Licensing Agreement with Richter-Helm BioTec 41

Stada Arzneimittel Enters Into License Agreement With Apotex For Filgrastim 42

Clinigen Enters Into Licensing Agreement With BL&H For Foscavir 44

Equity Offering 45

Telesta Therapeutics Raises USD0.2 Million in Private Placement of Shares 45

Debt Offering 46

Stada Arzneimittel Announces Private Placement of Bonds Due 2022 for USD325.5 46

Stada Arzneimittel Completes Private Placement Of Bonds Due 2018 For USD 452 Million 47

Asset Transactions 48

DMN Invest Acquires Two Drug Manufacturing Facilities From Stada Arzneimittel 48

Acquisition 49

Nidda Healthcare to Acquire Stake in Stada Arzneimittel 49

Elliott Management May Acquire Stake in Stada Arzneimittel 50

STADA Arzneimittel to Acquire Laboratorio Vannier for USD13 Million 51

STADA Arzneimittel Acquires SCIOTEC Diagnostic Technologies for USD19.8 Million 52

Stada Arzneimittel Completes Acquisition Of Thornton & Ross, OTC Drug Maker, For USD 339 Million 53

Sun Pharma Mulls Acquisition Of Stada Arzneimittel 55

Stada Arzneimittel AG-Key Competitors 56

Stada Arzneimittel AG-Key Employees 57

Stada Arzneimittel AG-Locations And Subsidiaries 58

Head Office 58

Other Locations & Subsidiaries 58

Recent Developments 61

Financial Announcements 61

Aug 09, 2018: STADA's business development in the first six months of 2018 as expected 61

May 03, 2018: STADA with solid business development in the first quarter of 2018 63

Mar 08, 2018: STADA records positive business development in 2017 65

Nov 09, 2017: STADA shows good business development in the third quarter of 2017 and the first nine months 68

Corporate Communications 70

Sep 03, 2018: Peter Goldschmidt to succeed Claudio Albrecht as STADA's CEO 70

Apr 16, 2018: Changes in the management team of STADA 71

Feb 01, 2018: Supervisory Board of STADA Arzneimittel appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018 72

Feb 01, 2018: Peter Goldschmidt to succeed Claudio Albrecht as CEO on 1 September 2018 73

Jul 04, 2017: STADA Arzneimittel appoints new Chief Executive Officer and Chief Financial Officer-incumbents step down from their positions 74

Apr 24, 2017: Dr. Ralph Grobecker to become Managing Director of STADA's OTC segment 75

Other Significant Developments 76

Sep 12, 2018: STADA invites the holders of the STADA Bond to participate in the bondholders meeting and to vote in favor of the proposed resolutions 76

Mar 08, 2018: CEO Albrecht to modernize STADA-Biosimilars to focus on oncology, CNS, diabetes and ophthalmology 77

Aug 03, 2017: STADA shows good operational development in first six months of 2017 78

Appendix 81

Methodology 81

About GlobalData 81

Contact Us 81

Disclaimer 81


List Of Figure

List of Figures

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Stada Arzneimittel AG, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Stada Arzneimittel AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Stada Arzneimittel AG, Deals By Therapy Area, 2012 to YTD 2018 10

Stada Arzneimittel AG, Medical Devices Deals, 2012 to YTD 2018 12

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Stada Arzneimittel Acquires Nizoral from Janssen Pharma 15

STADA Arzneimittel Acquires AndroDoz and NeroDoz from OOO PharmEnergy for USD7.9 Million 16

Thornton & Ross Acquires Rights for Flexitol from LaCorium Health for USD17 Million 17

Nizhpharm Completes Acquisition Of Aqualor Product Portfolio For USD 178 Million 18

STADA Arzneimittel Completes Acquisition Of Generics Business From Spirig Pharma For USD 108 Million 19

STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For USD 230 Million 20

Bristol-Myers Squibb May Sell UPSA to BC Partners, CVC Capital, PAI Partners and STADA for USD1.16 Billion 22

Ardian May Sell Riemser Pharma for USD494.3 Million 24

Bain Capital and Cinven Partners to Acquire Stada Arzneimittel 26

Bain Capital Private Equity and Cinven Partners Renew the Terms to Acquire Stada Arzneimittel 28

Xbrane Biopharma and STADA Arzneimittel Enter into Co-Development Agreement 30

Enzymatica Enters into Distribution Agreement with STADA for ColdZyme 31

Theratechnologies Enters into Commercialization Agreement with BL&H 32

Stada Arzneimittel to Form Joint Venture with Hetero Drugs 33

Claris Lifesciences Enters into Distribution Agreement with Stada Arzneimittel 34

BL&H Enters into Licensing Agreement with Race Oncology 35

BL&H Enter into Licensing Agreement with MDNA Life Sciences 36

Thornton & Ross Enters into Licensing Agreement with Futura Medical 37

BL&H Enters into Licensing Agreement with Telesta Therapeutics 38

STADA Arzneimittel Enters into Licensing Agreement with Gedeon Richter 39

Stada Arzneimittel to Enter into Licensing Agreement with mAbxience 40

Stada Arzneimittel Enters into Licensing Agreement with Richter-Helm BioTec 41

Stada Arzneimittel Enters Into License Agreement With Apotex For Filgrastim 42

Clinigen Enters Into Licensing Agreement With BL&H For Foscavir 44

Telesta Therapeutics Raises USD0.2 Million in Private Placement of Shares 45

Stada Arzneimittel Announces Private Placement of Bonds Due 2022 for USD325.5 46

Stada Arzneimittel Completes Private Placement Of Bonds Due 2018 For USD 452 Million 47

DMN Invest Acquires Two Drug Manufacturing Facilities From Stada Arzneimittel 48

Nidda Healthcare to Acquire Stake in Stada Arzneimittel 49

Elliott Management May Acquire Stake in Stada Arzneimittel 50

STADA Arzneimittel to Acquire Laboratorio Vannier for USD13 Million 51

STADA Arzneimittel Acquires SCIOTEC Diagnostic Technologies for USD19.8 Million 52

Stada Arzneimittel Completes Acquisition Of Thornton & Ross, OTC Drug Maker, For USD 339 Million 53

Sun Pharma Mulls Acquisition Of Stada Arzneimittel 55

Stada Arzneimittel AG, Key Competitors 56

Stada Arzneimittel AG, Key Employees 57

Stada Arzneimittel AG, Subsidiaries 58

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Stada Arzneimittel AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.